CUTISS closes successful series B financing round

Swiss biotech startup CUTISS announced the closing of its Series B round led by Giammaria Giuliani (Gisev Family Office), seconded by the Wyss Foundation and supported by new and existing private investors and family offices.

CUTISS is a Swiss life science company, spin-off of the University of Zurich, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its lead product candidate, denovoSkin™, has been tested in phase I clinical trial on pediatric patients at the University Children’s Hospital in Zurich. 

Today, the CEO Daniela Marino announced it has successfully secured a CHF 18.7 million series B financing round. But the target is set to reach CHF 20 milion until the 15th of June. 

CUTISS ranked in the TOP 100 Swiss Startup Award since 2017 and was selected amongst the 10 best Swiss startups for the Venture Leaders Life Sciences investors roadshow in 2018. They also

"The roadshow was an invaluable experience, I had the opportunity to expose our tissue engineering business to a major life sciences hub, to build my entrepreneurship skills and network at the same time. So missing out wasn’t an option" Daniela Marino, CEO at CUTISS



Source: CUTISS press release